Nearly a year ago now, the American Society of Clinical Oncology (ASCO) first announced plans to initiate an innovative trial of a personalized medicine initiative called the Targeted Agent and Profiling Utilization Registry (TAPUR) study. Prostate cancer patients are eligible to participate in the TAPUR study if: They have advanced prostate cancer that has Stopped […]![]()
